Assistant Secretary for Preparedness and Response

Description

Synopsis: BARDA encourages the advanced research, development and acquisition of medical countermeasures such as vaccines, therapeutics, and diagnostics, as well as innovative approaches to meet the threat of Chemical, Biological, Radiological and Nuclear (CBRN) agents in support of the preparedness mission and priorities of the HHS Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) articulated in the 2014 PHEMCE Implementation Plan for CBRN Threats. The Implementation Plan is located on the ASPR website: http://www.phe.gov/Preparedness/mcm/phemce/Documents/2014-phemce-sip.pdf The Pandemic and All Hazard Preparedness Act Pub. L. No. 109-417, 42 U.S.C. § 241 et seq. (PAHPA; http://www.gpo.gov/fdsys/pkg/PLAW-109publ417/pdf/PLAW-109publ417.pdf) and The Pandemic and All Hazard Preparedness Reauthorization Act Pub. L. No. 113-5, (PAHPRA: http://www.gpo.gov/fdsys/pkg/PLAW-113publ5/pdf/PLAW-113publ5.pdf) authorizes BARDA to (i) conduct ongoing searches for, and support calls for, potential qualified countermeasures and qualified pandemic or epidemic products; (ii) direct and coordinate the countermeasure and product advanced research and development activities of the Department of Health and Human Services; (iii) establish strategic initiatives to accelerate countermeasure and product advanced research and development (which may include advanced research and development for purposes of fulfilling requirements under the Federal Food, Drug, and Cosmetic Act or section 351 of this Act) and innovation in such areas as the Secretary may identify as priority unmet need areas; and (iv) award contracts, grants, cooperative agreements, and enter into other transactions, for countermeasure and product advanced research and development.Areas of Interest:The purpose of this BAA is to solicit proposals that focus on one or more of the following areas of interest as listed here and further described in Part I.Research Areas of Interest:1. Vaccines 2. Antitoxins and Therapeutic Proteins3. Antimicrobial Therapeutics4. Radiological/Nuclear Threat Medical Countermeasures5. Chemical Threat Medical Countermeasures6. Clinical DiagnosticsBARDA anticipates that research and development activities awarded from this Broad Agency Announcement (BAA) will serve to advance the knowledge and scientific understanding of candidates' countermeasures for CBRN threats toward eventual FDA approval and their inclusion in the Strategic National Stockpile (SNS).

Who can apply

• Unrestricted

Contact

George J. Keane, Contracting Officer, george.keane@hhs.gov, Phone: 2022605169
george.keane@hhs.gov